Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating young patients with acute lymphoblastic leukemia.

PURPOSE: Thisphase III trial is studying several different combination chemotherapy regimens to compare how well they work in treating young patients with acute lymphoblastic leukemia.

Conditions

• Leukemia

Interventions

DRUG

asparaginase

DRUG

cyclophosphamide

DRUG

cytarabine

DRUG

daunorubicin hydrochloride

DRUG

dexamethasone

DRUG

doxorubicin hydrochloride

DRUG

etoposide

DRUG

ifosfamide

DRUG

mercaptopurine

DRUG

methotrexate

DRUG

prednisone

DRUG

thioguanine

DRUG

vincristine sulfate

DRUG

vindesine

RADIATION

radiation therapy

Sponsors & Collaborators

• University Hospital Schleswig-Holstein

  lead OTHER

Principal Investigators

• Martin Schrappe, MD, PhD · University Hospital Schleswig-Holstein

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

FACTORIAL

Eligibility

Min Age

1 Year

Max Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2000-07-31

Primary Completion

2012-01-31

Completion

2012-01-31

Countries

• Austria
• Germany
• Switzerland

Study Locations